Remember when the promise of biotech was a mere twinkle of innovation in some researcher’s eyes? An investor’s long-term bet? Depending on how you label a biotech company, Amgen Inc.’s first-ever payment of a quarterly dividend last week marks an…
Bad Behavior has blocked 819 access attempts in the last 7 days.
Join the Conversation